Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Zoetis Launches New Doggy Med for Noise-Related Anxiety

By Drug Discovery Trends Editor | May 16, 2016

Fido and Spot may not have to cower under the bed this summer when fireworks and thunderstorms hit, thanks to the first prescription veterinary medicine for treating anxiety over loud noises — a widespread problem that causes property destruction, terrified dogs running away and even life-threatening injuries or euthanasia for some.

Veterinary medicine maker Zoetis Inc. of Florham Park, New Jersey, said Monday that recently approved Sileo will be available through veterinarians within a week.

It’s a much-needed option for dogs not helped enough by repurposed medicines designed for their humans, or by rarely effective behavioral strategies.

Owners of at least one-third of the 70 million dogs in the U.S. report problems with fear of loud noises. Dogs are sometimes so frightened they jump through plate-glass windows, destroy doors while trying to escape a room or run into traffic and get hit by cars. As a result, July 5 is the most common day for frustrated pet owners to drop a dog off at a shelter, which sometimes leads to the animal being euthanized.

“I have seen the absolutely worst things that can happen with noise anxiety,” Dr. J. Michael McFarland, head of U.S. pet marketing at Zoetis, told The Associated Press in an exclusive interview.

The anxiety gets worse over time without treatment and is much like posttraumatic stress disorder in humans, said McFarland, a veterinarian who earlier in his career spent a quarter-century working at animal hospitals, including running one of the first after-hours emergency pet hospitals in the country.

Current treatments range from human anti-anxiety pills such as Xanax and tranquilizers that sedate dogs for many hours but don’t really calm them to behavioral treatments. Those include confining the dog to a small room or portable kennel, or trying to desensitize dogs by repeatedly exposing them to increasingly loud noise, which McFarland said he’s never seen work. Another option is close-fitting shirts that comfort some dogs with minor noise problems by simulating a hug.

Sileo works by blocking norepinephrine, a brain chemical similar to adrenaline that pumps up anxiety. It comes in prefilled plastic syringes with a dial for setting a precise dose according to the dog’s weight.

The needleless syringe is placed between the dog’s gum and lip. A little push ejects a small amount of gel that’s absorbed by the tissue lining the dog’s cheek, which limits how much circulates in the dog’s body at a time while enabling the medicine to start working within 30 to 60 minutes. It works for two to three hours, said McFarland, who’s used Sileo with good results on his Finnish Lapphund.

Each syringe costs $30, about two doses for an 80- to 100-pound dog or fours doses for a 40-pound dog.

Zoetis has exclusive rights to distribute Sileo in the U.S. under an agreement with its developer, Orion Corp. of Finland.

In testing on 182 pet beagles conducted on New Year’s Eve, 75 percent of their owners rated its effect good or excellent, compared with 33 percent whose dogs got a placebo. Side effects were rare and minor.

In another study, 90 percent of pet owners said it was easy or very easy to administer.

Zoetis is a top maker of medicines and vaccines for pets and livestock, including Apoquel for itchy skin from dermatitis and Rimadyl for pain from arthritis and surgery. Formerly part of drugmaker Pfizer Inc., Zoetis operates in more than 100 countries and reported revenue of $4.8 billion last year.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE